14. "Selective Heteroaryl N-Oxidation of Amine-Containing Molecules" R. M. B. Dyer, P. L. Hahn, M. K. Hilinski, Org. Lett. 2018, 20, 2011-2014.
13. "Organocatalytic Nitrenoid Transfer: Metal-Free Selective Intermolecular C(sp3)-H Amination Catalyzed by an Iminium Salt" L. A. Combee, B. Raya, D. Wang, M. K. Hilinski, Chem. Sci. 2018, 9, 935-939.
- Highlighted in Synfacts. "Synfact of the Month" for Organo- and Biocatalysis
12. "Organocatalytic, Dioxirane-Mediated C–H Hydroxylation Under Mild Conditions Using Oxone" W. G. Shuler, S. L. Johnson, M. K. Hilinski, Org. Lett. 2017, 19, 4790-4793.
- Top 20 most read paper in Organic Letters for a month following publication
11. "An Iminium Salt Organocatalyst for Selective Aliphatic C–H Hydroxylation" D. Wang, W. G. Shuler, C. J. Pierce, M. K. Hilinski, Org. Lett. 2016, 18, 3826-3829.
10. "Intermolecular Electrophilic Addition of Epoxides to Alkenes: [3+2] Cycloadditions Catalyzed by Lewis Acids" W. G. Shuler, L. A. Combee, I. D. Falk, M. K. Hilinski, Eur. J. Org. Chem. 2016, 3335–3338.
- Highlighted in Org. Chem. Highlights 2017, April 10.
9. "Chemoselective Hydroxylation of Aliphatic sp3 C–H Bonds Using a Ketone Catalyst and Aqueous H2O2" C. J. Pierce, M. K. Hilinski, Org. Lett. 2014, 16, 6504–6507.
- Top 5 most-read paper in Organic Letters from Dec 2014 – Jan 2015
- Highlighted in Synfacts
Graduate and Postdoctoral Research:
8. “Improving the Affinity of SL0101 for RSK Using Structure-Based Design” R. M. Mrozowski, R. Vemula, B. Wu, Q. Zhang, B. R. Schroeder, M. K. Hilinski, D. E. Clark, S. M. Hecht, G. A. O’Doherty, D. A. Lannigan, ACS Med. Chem. Lett. 2013, 4, 175–179.
7. “Insights into the Inhibition of the p90 Ribosomal S6 Kinase (RSK) by the Flavonol Glycoside SL0101 from the 1.5 Å Crystal Structure of the N-Terminal Domain of RSK2 with Bound Inhibitor” D. Utepbergenov, U. Derewenda, N. Olekhnovich, G. Szukalska, B. Banerjee, M. K. Hilinski, D. A. Lannigan, P. T. Stukenberg, Z. S. Derewenda, Biochemistry 2012, 51, 6499–6510.
6. “Analogues of the RSK Inhibitor SL0101: Optimization of In Vitro Biological Stability” M. K. Hilinski, R. M. Mrozowski, D. E. Clark, D. A. Lannigan, Bioorg. Med. Chem. Lett. 2012, 22, 3244–3247.
5. “Function-Oriented Synthesis: Biological Evaluation of Laulimalide Analogues Derived from a Last Step Cross Metathesis Diversification Strategy.” S. L. Mooberry, M. K. Hilinski, E. A. Clark, P. A. Wender Mol. Pharmaceutics 2008, 5, 829–838.
4. “Beyond Natural Products: Synthetic Analogs of Bryostatin 1” P. A. Wender, J. L. Baryza, M. K. Hilinski, J. C. Horan, C. Kan, V. A. Verma in Drug Discovery Research: New Frontiers in the Post-Genomic Era; Huang, Z., Ed.; John Wiley & Sons: New York, NY, 2007.
3. “Pharmacophore Mapping in the Laulimalide Series: Total Synthesis of a Vinylogue for a Late-Stage Metathesis Diversification Strategy.” P. A. Wender, M. K. Hilinski, P. R. Skaanderup, N. G. Soldermann, S. L. Mooberry Org. Lett. 2006, 8, 4105–4108.
2. “Total Synthesis and Biological Evaluation of 11-Desmethyllaulimalide, a Highly Potent Simplified Laulimalide Analogue.” P. A. Wender, M. K. Hilinski, N. Soldermann, S. L. Mooberry Org. Lett. 2006, 8, 1507–1510.
1. “Late-Stage Intermolecular CH Activation for Lead Diversification: A Highly Chemoselective Oxyfunctionalization of the C-9 Position of Potent Bryostatin Analogues.” P. A. Wender, M. K. Hilinski, A. V. W. Mayweg Org. Lett. 2005, 7, 79–82.
